Fundraising Fox
InCarda Therapeutics
Brisbane, US · Founded 2009 · Delaware corporation · 11 employees on LinkedIn · 6 known investors
Find your way into InCarda Therapeutics
Sign up to see every warm intro you have to InCarda Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InCarda Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
Founders & leadership
InCarda Therapeutics was founded in 2009 by Carlos A. Schuler and John S. Patton.
CA
Carlos A. SchulerChief Technology Officer and Co-founderCarlos A. Schuler is Executive Officer and Director at InCarda Therapeutics, which develops drug therapies for treating atrial fibrillation. He brings over 30 years of cross-functional engineering and management experience.
JS
John S. PattonCo-founder, Executive Chairman2008–2015John S. Patton co-founded Inhale (later Nektar Therapeutics) in 1990, which developed inhaled insulin delivery technology and reached a $2.1 billion valuation on NASDAQ in 2001, and has since founded or co-founded multiple drug development companies including Dance Biopharm, InCarda Therapeutics, iPharma, and Tesio Pharmaceuticals, focusing on novel delivery platforms and therapeutic agents across cardiovascular, respiratory, and inflammatory indications.
RN
Rangachari NarasimhanExecutive
GC
Grace ColonAdvisor2022–2023Grace Colon served as CEO of InCarda Therapeutics, where she raised $120M and advanced the company's lead atrial fibrillation candidate from preclinical through Phase 3 development. She brings over 25 years of experience in biopharma, diagnostics, and venture capital, with prior leadership roles at Gilead Sciences, Intrexon, and Affymetrix, and has served on multiple public and private company boards.
MS
Miller SamanthaExecutive
Board
MR
McCarthy ReenieBoard director
BN
Bischofberger NorbertBoard director
Investors · 6
Asset Management Companylisted by Asset Management CompanyMenlo Park · $500K – $2M
How we know: Asset Management Company's portfolio page · Not right? Tell us
HealthCaplisted by HealthCapStockholmvia Johan Christenson · board
How we know: HealthCap's portfolio page · board seat on SEC Form D · fiercebiotech.com · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 2
InnovivaleadMorningside Ventures
Reported raises · per SEC filings
Form D private placements$66M disclosed across 4 of 5 rounds · 2013–2020
▶$28MraisedOct 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$28MraisedOct 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew ElBardissiDirector
- Johan ChristensonDirector
- Alan ColowickDirector
- Isaac ChengDirector
- Grace ColonExecutive Officer, Director
- Dan WelchDirector
- Offering amount
- $50M
- Amount sold
- $28M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.3MraisedNov 2019 · 24 investors · PharmaceuticalsRule 506(b)
▶$35.3MraisedNov 2019 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Grace ColonExecutive Officer, Director
- Isaac ChengDirector
- Bischofberger NorbertDirector
- Alan ColowickDirector
- Johan ChristensonDirector
- Andrew ElBardissiDirector
- Dan WelchDirector
- Offering amount
- $42.1M
- Amount sold
- $35.3M
- Minimum investment
- $1.8K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedMay 2017 · 16 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedMay 2017 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rangachari NarasimhanExecutive Officer, Director
- McCarthy ReenieDirector
- Grace ColonExecutive Officer, Director
- Bischofberger NorbertDirector
- Miller SamanthaExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- Minimum investment
- $5K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$567KraisedDec 2014 · 13 investors · PharmaceuticalsRule 506(b)
▶$567KraisedDec 2014 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Grace ColonExecutive Officer, Director
- Carlos A. SchulerExecutive Officer, Director
- Rangachari NarasimhanExecutive Officer, Director
- John S. PattonExecutive Officer, Director
- Offering amount
- $12.9M
- Amount sold
- $567K
- First sale
- Sep 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through InCarda Therapeutics went on to found or lead other companies.
Related companies · 2
CardurionCardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
Companies working in the same space as InCarda Therapeutics.
In the news
Frequently asked questions
- What does InCarda Therapeutics do?
- Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
- Who founded InCarda Therapeutics?
- InCarda Therapeutics was founded by Carlos A. Schuler, John S. Patton in 2009.
- Who are InCarda Therapeutics's investors?
- InCarda Therapeutics's investors include Asset Management Company, HealthCap, Sofinnova Ventures, Deerfield Management Company.
- How much funding has InCarda Therapeutics raised?
- InCarda Therapeutics has disclosed $66M raised across 4 of its 5 known rounds.
- Where is InCarda Therapeutics headquartered?
- InCarda Therapeutics is headquartered in Brisbane, US.